Venrock Adviser
NEW YORK, NYfiles as Venrock Adviser, LLC
$3.3bn in 33 US stocks at the end of 30 June 2026. The top 10 are 80.4% of the money. It changed about 15.7% of the portfolio this quarter.
Value
$3.3bn
Stocks
33
Top 10 share
80.4%
Turnover
15.7%
What changed this quarter
New
Bought for the first time this quarter.
- Achieve Life SciencesACHV0.5% of the fund
- Parabilis MedicinesPBLS0.5% of the fund
- Research Alliance Corp IIIRACC<0.1% of the fund
- InMed PharmaceuticalsINM<0.1% of the fund
Added
Bought more of a stock they already held.
- ErascaERAS9.9% of the fund+9%
- SavaraSVRA2.8% of the fund+7%
- Relmada TherapeuticsRLMD1.4% of the fund+41%
- Artiva BiotherapeuticsARTV0.6% of the fund+27%
- X4 PharmaceuticalsXFOR0.3% of the fund+485%
Cut
Sold some of their stake.
- Spyre TherapeuticsSYRE8.0% of the fund-19%
- Cogent BiosciencesCOGT1.9% of the fund-18%
- Viridian TherapeuticsVRDN1.8% of the fund-16%
- Enliven TherapeuticsELVN0.8% of the fund-70%
- CytomX TherapeuticsCTMX0.6% of the fund-50%
Sold out
Sold their entire stake.
- Kalvista Pharmaceuticals-100%
- Engene Holdings-100%
- Tenax TherapeuticsTENX-100%
- SepternaSEPN-100%
Holdings
- Apogee TherapeuticsAPGE
- Share
- 34.2%
- Value
- $1.1bn
- Shares
- 8,493,321
Held
- Damora Therapeutics
- Share
- 2.8%
- Value
- $94m
- Shares
- 3,603,595
Held
- Adlai NortyeANL
- Share
- 1.1%
- Value
- $37m
- Shares
- 3,212,731
Held
- Helus PharmaHELP
- Share
- 0.8%
- Value
- $25m
- Shares
- 3,851,654
Held
- Parabilis MedicinesPBLS
- Share
- 0.5%
- Value
- $17m
- Shares
- 625,000
New
- Research Alliance Corp IIIRACC
- Share
- <0.1%
- Value
- $3m
- Shares
- 300,000
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Apogee TherapeuticsAPGE | 34.2% | $1.1bn | 8,493,321 | Held |
| Oruka TherapeuticsORKA | 12.0% | $395m | 4,148,428 | Held |
| ErascaERAS | 9.9% | $328m | 17,891,812 | +9% |
| Spyre TherapeuticsSYRE | 8.0% | $265m | 2,985,448 | -19% |
| Dianthus TherapeuticsDNTH | 3.5% | $115m | 1,180,000 | Held |
| Ocular TherapeutixOCUL | 3.1% | $102m | 10,346,926 | Held |
| Damora Therapeutics | 2.8% | $94m | 3,603,595 | Held |
| SavaraSVRA | 2.8% | $91m | 14,745,943 | +7% |
| Jade BiosciencesJBIO | 2.2% | $72m | 3,220,364 | Held |
| Cogent BiosciencesCOGT | 1.9% | $64m | 1,642,166 | -18% |
| Viridian TherapeuticsVRDN | 1.8% | $60m | 3,257,917 | -16% |
| Vor BiopharmaVOR | 1.7% | $56m | 3,041,719 | Held |
| Dyne TherapeuticsDYN | 1.5% | $48m | 2,173,913 | Held |
| Maze TherapeuticsMAZE | 1.4% | $48m | 1,602,034 | Held |
| Relmada TherapeuticsRLMD | 1.4% | $47m | 6,844,305 | +41% |
| Oric PharmaceuticalsORIC | 1.4% | $47m | 4,319,765 | Held |
| Crescent BiopharmaCBIO | 1.2% | $38m | 2,133,576 | Held |
| Zura BioZURA | 1.2% | $38m | 6,434,990 | Held |
| Adlai NortyeANL | 1.1% | $37m | 3,212,731 | Held |
| Enliven TherapeuticsELVN | 0.8% | $27m | 526,331 | -70% |
| Helus PharmaHELP | 0.8% | $25m | 3,851,654 | Held |
| Cullinan TherapeuticsCGEM | 0.8% | $25m | 1,379,965 | Held |
| Century TherapeuticsIPSC | 0.6% | $21m | 8,695,652 | Held |
| Artiva BiotherapeuticsARTV | 0.6% | $20m | 2,043,596 | +27% |
| CytomX TherapeuticsCTMX | 0.6% | $19m | 4,982,124 | -50% |
| Achieve Life SciencesACHV | 0.5% | $18m | 2,751,032 | New |
| Parabilis MedicinesPBLS | 0.5% | $17m | 625,000 | New |
| SurrozenSRZN | 0.5% | $16m | 632,931 | Held |
| Korro BioKRRO | 0.4% | $13m | 1,009,500 | Held |
| Alto NeuroscienceANRO | 0.4% | $13m | 500,000 | Held |
| X4 PharmaceuticalsXFOR | 0.3% | $9m | 1,934,253 | +485% |
| Research Alliance Corp IIIRACC | <0.1% | $3m | 300,000 | New |
| InMed PharmaceuticalsINM | <0.1% | $50,662 | 32,685 | New |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 147.1% since 30 June 2025.
Where the money is
Health care96.0%
Other4.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.